[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112013001879A2 - "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe" - Google Patents

"método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe"

Info

Publication number
BR112013001879A2
BR112013001879A2 BR112013001879A BR112013001879A BR112013001879A2 BR 112013001879 A2 BR112013001879 A2 BR 112013001879A2 BR 112013001879 A BR112013001879 A BR 112013001879A BR 112013001879 A BR112013001879 A BR 112013001879A BR 112013001879 A2 BR112013001879 A2 BR 112013001879A2
Authority
BR
Brazil
Prior art keywords
gastric cancer
bevacizumab
treatment effect
kit
improving
Prior art date
Application number
BR112013001879A
Other languages
English (en)
Inventor
Foernzler Dorothee
Delmar Paul
Scherer Stefan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112013001879A2 publication Critical patent/BR112013001879A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395Alveolar surfactant peptides; Pulmonary surfactant peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57446Specifically defined cancers of stomach or intestine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

"método para aperfeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um oligonucleotídeo ou polipeptídio e uso de bevacizumabe" trata-se de métodos para aperfeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, em particular, adenocarcinoma do estômago ou da junção gastroesofagiana ("gej"), pelo tratamento com bevacizumabe (avastin®) em combinação com um regime de quimioterapia pela determinação do nível de expressão de neuropilina em relação a um nível de controle determinado em pacientes que sofrem de câncer gástrico, em particular, adenocarcinoma do estômago ou da junção gastroesofagiana ("gej"). o efeito de tratamento aperfeiçoado pode ser sobrevivência geral aperfeiçoada ou sobrevivência livre de progressão aperfeiçoada. a presente invenção fornece adicionalmente métodos para avaliar a sensibilidade ou a responsividade de um paciente ao bevacizumabe (avastin®) em combinação com um regime de quimioterapia, pela determinação do nível de expressão da neuropilina em relação a um nível de controle determinado em pacientes que sofrem de câncer gástrico, em particular, adenocarcinoma do estômago ou da junção gastroesofagiana ("gej").
BR112013001879A 2010-08-13 2011-08-12 "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe" BR112013001879A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10172812 2010-08-13
PCT/EP2011/063932 WO2012020123A2 (en) 2010-08-13 2011-08-12 Neuropilin as a biomarker for bevacizumab combination therapies

Publications (1)

Publication Number Publication Date
BR112013001879A2 true BR112013001879A2 (pt) 2019-09-03

Family

ID=44543220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001879A BR112013001879A2 (pt) 2010-08-13 2011-08-12 "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe"

Country Status (12)

Country Link
US (3) US20130171134A1 (pt)
EP (1) EP2603239A2 (pt)
JP (1) JP2013539460A (pt)
KR (1) KR20140003393A (pt)
CN (1) CN103052404A (pt)
AU (1) AU2011288354A1 (pt)
BR (1) BR112013001879A2 (pt)
CA (1) CA2806447A1 (pt)
MX (1) MX2013001523A (pt)
RU (1) RU2013110780A (pt)
SG (1) SG187109A1 (pt)
WO (1) WO2012020123A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366890B (es) 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
PT2841575T (pt) * 2012-04-27 2019-10-11 Millennium Pharm Inc Moléculas de anticorpo anti-gcc e utilização das mesmas para testar a suscetibilidade à terapia direcionada a gcc
WO2016115149A1 (en) * 2015-01-12 2016-07-21 Aveo Pharmaceuticals, Inc. Neuropilin-1 as a serum based biomarker
WO2021076852A1 (en) * 2019-10-17 2021-04-22 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2109686A2 (en) * 2007-01-18 2009-10-21 University Of Southern California Genetic markers for predicting responsiveness to combination therapy
KR101179843B1 (ko) * 2009-04-08 2012-09-04 경북대학교 산학협력단 뉴로필린 2의 위암 진단 및 치료용 용도
BR112012016229A2 (pt) * 2010-01-19 2017-03-07 Hoffmann La Roche método para melhorar a sobrevida livre de progressão, método in vitro, kit, uso de um oligonucleotídeo ou polipetídeo e uso de bevacizumab

Also Published As

Publication number Publication date
CA2806447A1 (en) 2012-02-16
CN103052404A (zh) 2013-04-17
KR20140003393A (ko) 2014-01-09
MX2013001523A (es) 2013-02-27
WO2012020123A9 (en) 2012-06-07
RU2013110780A (ru) 2014-09-20
EP2603239A2 (en) 2013-06-19
US20130171134A1 (en) 2013-07-04
US20130177554A1 (en) 2013-07-11
SG187109A1 (en) 2013-03-28
WO2012020123A3 (en) 2012-04-12
JP2013539460A (ja) 2013-10-24
AU2011288354A1 (en) 2013-01-24
US20130183304A1 (en) 2013-07-18
WO2012020123A2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
Bian et al. Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer
Pan et al. Tea polyphenol (−)-epigallocatechin 3-gallate suppresses heregulin-β1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
MY172580A (en) Tumor tissue based biomarkers for bevacizumab combination therapies
WO2010059969A8 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
Kim et al. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
BRPI0818318B8 (pt) composição imunoestimuladora ativa, seus usos, vacina, uso de pelo menos cinco rnas isolados, e kit
Bian et al. Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer
BRPI0906435B8 (pt) Anticorpo anti-cd79b quimérico, composto conjugado, formulação farmacêutica, método para determinar a presença da proteína cd79b, ensaio para detectar células de câncer, método para inibir proliferação celular, usos de um anticorpo, de um composto conjugado e de uma formulação farmacêutica, e método para a fabricação de um composto conjugado
NO20084546L (no) Diagnostikk og behandlinger for tumorer
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
BRPI0922350A2 (pt) anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra.
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
BR112016002000A2 (pt) Diagnóstico e terapia de câncer envolvendo células-tronco tumorais
MX343801B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
NZ602840A (en) Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
EP2068929A4 (en) METHOD OF DETECTING AND TREATING SKIN DISORDERS
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
BR112013001879A2 (pt) "método para aprefeiçoar o efeito de tratamento em um paciente que sofre de câncer gástrico, método in vitro, kit, uso de um olignucleotídeo ou polipetídio e uso de bevacizumabe"
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
AR089067A1 (es) Biomarcadores en el plasma sanguineo para terapias de combinacion de bevacizumab destinadas al tratamiento del cancer de mama
BR112013014195A2 (pt) Método para a identificação de um paciente, composição, uso de bevacizumabe para a preparação de uma composição farmacêutica, método para o tratamento de um distúrbio proliferativo e composição, uso ou método
AR084163A1 (es) Metodo para el diagnostico de un carcinoma y usos del mismo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]